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Background: Asthma guidelines recommend reducing inhaled corticosteroids (ICS) to the
minimum effective dose, but the timing of long-acting b2-agonist (LABA) withdrawal is unclear.
Recent FDA guidelines recommend LABA withdrawal once asthma is well-controlled. This 13-
month double-blind study of patients taking high-dose combination therapy investigated the
effect of discontinuation of LABA before ICS down-titration.
Methods: Adults using salmeterol/fluticasone combination (SFC) 50/500 mg bd were random-
ized to SFC 50/500 mg bd or fluticasone propionate (FP) 500 mg bd, with subsequent ICS
down-titration 8-weekly using a clinical algorithm. The primary outcome was mean daily FP
dose, including ICS for exacerbations.
Results: 82 subjects were randomized. Asthma was well-controlled at baseline, with mean FEV1
84.8% predicted and Asthma Control Questionnaire (ACQ) score 0.9. There was no significant
difference in mean daily FP dose (SFC: 721 mg, FP:816 mg, pZ 0.3), but final dose was lower with
SFC (534 mg cf. 724 mg, pZ 0.005). ICS dose was reduced by80% in 41% SFC and 15% FP patients.
Ambulatory lung function was significantly higher with SFC, but there were no differences
between groups in rescue b2-agonist use, clinic spirometry, airway responsiveness, ACQ, sputum
eosinophils or FeNO. Baseline airway responsiveness, and pre-reduction blood eosinophils, were
significant predictors of mean daily FP dose and dose reduction failure respectively.
Conclusions: Many patients prescribed high-dose combination therapy may be over-treated.
Substantial reductions in dose can be achieved with a clinical algorithm, reaching lower FP doses
with SFC than FP without losing asthma control or increasing disease activity.
Trial Registration: This study was commenced before mandatory registration of clinical trials.
ª 2010 Elsevier Ltd. All rights reserved.9114 0437; fax: þ61 2 9114 0014.
.au (H.K. Reddel).
0 Elsevier Ltd. All rights reserved.
Down-titration from high dose combination therapy in asthma 1111Introduction Study designFor patients whose asthma is not well-controlled on low-
moderate dose inhaled corticosteroids (ICS), addition of
long-acting b2-agonist (LABA) leads to better asthma
control than increasing the dose of ICS.1 If asthma is still
uncontrolled, international asthma guidelines2,3 advocate
stepping up the dose of ICS/LABA, but also stress the
importance of reducing medications once good asthma
control is achieved and maintained. However, there is still
considerable uncertainty about how and when treatment
should be stepped down. Most patients using ICS alone can
tolerate a reduction of 30e50%,4e7 although complete
cessation of ICS results in rapid loss of asthma control.4,8
Adding LABA to ICS allows the ICS dose to be reduced
without loss of asthma control.9 There was early concern
that if ICS dose was reduced rapidly, use of LABA, by
controlling symptoms, could mask the emergence of airway
inflammation,10 and there has been considerable interest in
identifying early predictors of loss of control during down-
titration.
One of the questions for clinical practice guidelines is
whether or when LABA itself should be withdrawn, in
stepping down from combination ICS/LABA treatment.
Current GINA guidelines state that “the preferred approach
is to begin by reducing the dose of inhaled glucocorticos-
teroid by approximately 50% while continuing the long-
acting b2-agonist”.
2 However, the US Food and Drug
Administration (FDA) recently ruled that “LABAs should be
used for the shortest duration of time required to achieve
control of asthma symptoms and discontinued, if possible,
once asthma control is achieved. Patients should then be
maintained on an asthma controller medication alone.”11
Previous research about withdrawal of LABA is limited to
moderate dose SFC, with two studies showing that removal
of LABA leads to lower lung function and less well-
controlled asthma than a single step-down to lower dose
SFC.12,13 No previous studies have examined removal of
LABA prior to down-titration from high dose ICS/LABA.
This investigator-initiated study was designed to compare
the effects of SFC versus FP alone during a programme of ICS
down-titration in asthmatic patients previously treated with
high dose ICS/LABA, and to assess factors predicting loss of
asthma control.
Methods
Study population
Male or female subjects aged 18e80 years were eligible if
they had a clinical diagnosis of asthma according to Amer-
ican Thoracic Society criteria for 6 months and had been
taking SFC for at least 4 weeks at a daily dose of 50/500 mg
bd either by Diskus or by pressurized metered dose inhaler.
Exclusion criteria were current smoking or >10 pack-year
smoking history, significant chronic respiratory disease or
evidence of extrathoracic airway obstruction, pregnancy or
lactation, use of oral/parenteral corticosteroids or hospi-
talization for asthma in the previous 3 months, or respira-
tory tract infection within the previous 4 weeks.This was a multi-centre, randomized, double-blind, parallel
group study (SAM40031). During a four-week run-in period,
subjects received open-label SFC 50/500 mg bd via Diskus.
Subjects were then eligible for randomization if they had
evidence of adequate unsupervised spirometric technique,
had completed >60% of run-in diary card sessions, and had
not experienced an exacerbation within the previous 4
weeks. The run-in period could be extended if necessary.
Subjects experiencing a severe exacerbation were with-
drawn but could be re-enrolled 3 months after cessation of
systemic corticosteroids.
Eligible subjects were randomized double-blind to SFC
50/500 mg bd or FP 500 mg bd by identical Diskus.
Randomization (week 0) was conducted by GSK Australia by
computer-generated schedule, stratified by duration of SFC
treatment (6 months, and >6 months), with a permuted
block design (block size of four randomization numbers).
The initial dose was continued after randomization for 12
weeks, the first 4 weeks to establish a post-randomization
baseline (Visit 3), and the remaining 8 weeks to assess for
initial down-titration (Visit 4). Thereafter subjects were
assessed for their eligibility for down-titration at 8-weekly
intervals (Visits 5e8) with final assessment of outcomes at
week 52 (Visit 9).
Study medication was provided at five dose levels (SFC
50/500 mg bd, 50/250 mg bd, 50/100 mg bd, 50/100 mg once
daily (od) and 0 mg od or FP 500 mg bd, 250 mg bd, 100 mg bd,
100 mg od, 0 mg od) in identical Diskus inhalers which were
identified by dose level and by a unique randomized pack
number in order to maintain blinding and concealment of
randomization allocation. Treatment with asthma medica-
tions, other than the study medications and corticosteroids
for exacerbations, was not permitted.
Subjects carried out twice daily electronic monitoring of
symptoms, medication use and spirometry throughout the
study using MicroDiaryCard electronic diary spirometers
(Micro Medical Ltd, Rochester, Kent UK); these devices have
inbuilt quality assurance checks which deliver immediate
on-screen prompts to subjects to repeat spirometric
maneuvers if necessary, e.g. for cough or hesitation. Prior
to visits, study medications were withheld for 12 h and
rescue b2-agonist for 6 h. After study questionnaires had
been completed, the fractional concentration of exhaled
nitric oxide (FeNO) was measured by the offline method.14
The subject exhaled against a small resistance to residual
volume into an NO impermeable polyethylene bag (Scholle
Industries Pty Ltd, SA, Australia) at an exhaled flow of
10 L/min, with diversion of the first 2 s of exhalation using
a three way tap. The exhaled gas from a single breath
was analysed within 6 h of collection using a chem-
iluminescence analyser (Thermo Environmental NOx Model
42C, Thermo Fisher Scientific, Waltham, MA, USA). The
normal range for FeNO was defined as less than 13.0 ppb15
Spirometry was performed according to ATS criteria.16
Predicted normal values were calculated using reference
tables from the European Community for Steel and Coal
study.17 At visits 3e9, methacholine challenge was per-
formed by the rapid method18 to a cumulative dose of
12.2 mmol, with calculation of the provocative dose causing
1112 H.K. Reddel et al.a 20% fall in FEV1 (PD20). Then, after administration of
200e400 mg salbutamol by large volume spacer, sputum
induction was performed by the method of Djukanovic with
4.5% saline.19 For each individual, the cumulative nebu-
lisation time (10 min or 15 min) was held constant at each
visit throughout the study. Sputum was processed using
a modification of the method of Gibson et al.20 Sputum
plugs were selected from the sample and incubated with
0.1% dithiothreitol (Sputolysin Calbiochem, diluted 1:10)
for 30 min at room temperature in a shaking water bath or
rotated at room temperature. Once dispersed, phosphate
buffered saline (PBS, 1% BSA) containing 30% dimethyl
sulphoxide (DMSO) was added to the sample 1:1, and the
sample was frozen for up to 10 days at 20 C.21 The
samples were batched and transported to New Lambton
where they were thawed, filtered, and a total cell count
performed. Phosphate buffered saline (PBS) was added to
the cell pellet to achieve 1  106 cells per ml, then two
Cytospin slides were prepared. The air-dried slides were
fixed in Quick Dip fixative (>60% v/v with Quick Dip II) for
10 min then stained with Diff Quik stain (Lab Aids Pty Ltd).
Four hundred non-squamous cells were counted and the
percentage of each cell type obtained. Personal allergen
exposure was measured prior to Visits 3e9 using intra-nasal
allergen samplers22 (Inhalix, Camperdown, Australia) which
were worn for 30 min on the evening prior to each visit.
Samples were stained with monoclonal antibodies to house
dust mite (Indoor Biotechnologies) and with the subject’s
own serum from the same visit, and the number of IgE-
staining particles and level of Dermatophagoides pter-
onyssinus 1 reported.
The study was conducted in accordance with the Decla-
ration of Helsinki, and the protocol was approved by the
Ethics Committees of Royal Prince Alfred Hospital (X01-
0274), Hunter New England Area Health Service (02/04/10/
3.01) and ConcordHospital (CH62/6/2004-048). All subjects
gave written informed consent. The study was commenced
prior to mandatory registration for clinical trials.Dose titration and exacerbations
Eligibility for dose reduction was based on Total Asthma
Score (TAS, range 0e12, see Additional Material), which had
components for symptoms, reliever use and PEF variability.
At Visits 4e8, study medication was reduced by one dose
level if TAS was stable or lower than the previous visit or all
subscores were 1. Step-down was not permitted if exac-
erbation medication had been used within the previous four
weeks, or if a severe exacerbation had occurred in the
previous eight weeks. If TAS increased by 2 compared
with the previous visit, study medication was increased by
one dose level.
Exacerbations were managed according to defined
protocols. Moderate exacerbations were defined by an
increase in rescue b2-agonist use by 2 occasions and/or
a fall in PEF by 2 standard deviations (SD) from baseline
mean on 2 of 3 consecutive days. Study medication was
doubled for 2 weeks; if necessary, FP 250 mg bd could be
added for two weeks. Severe exacerbations were defined
as increase in rescue b2-agonist by 2 occasions in a day
compared with baseline and a fall in PEF by 3 SD frombaseline mean on 2 of 3 consecutive days. Subjects were
treated with prednisolone 50 mg/day for 5 days and
doubling of study medication for 14 days. Subjects on
Level 5 treatment who did not recover after 2 weeks of
doubled study medication could be withdrawn at the
investigator’s discretion. Trigger points for exacerbations
(rescue use and PEF) were calculated at Week 0, and re-
established after 4 weeks on randomized medication.
After exacerbation treatment, subjects resumed their
previous dose level, except if the exacerbation had
occurred in the first four weeks after a dose reduction, in
which case they returned to the previous higher level until
the next visit.
Outcome measures
The primary efficacy evaluation was average daily FP dose
(mg/day) from randomization (week 0) to completion or
withdrawal, including study medication and exacerbation
medication. Secondary evaluations included minimum
effective FP dose, defined as the lowest dose at which
a subject remained exacerbation-free between two
consecutive visits and TAS did not increase by 2. If down-
titration was attempted, Dose Reduction Failure was
defined if an exacerbation occurred prior to the next visit
and/or TAS increased by 2. Secondary measures included
FEV1 and FVC, PD20 methacholine, Asthma Control Ques-
tionnaire (ACQ),23 Asthma-related Quality of Life Ques-
tionnaire (AQLQ),24 Optimal Asthma Control (defined as TAS
4, PD20  1.0 mmol and no exacerbation in previous 4
weeks), % sputum eosinophils and neutrophils, blood
eosinophils, exacerbations, and exhaled nitric oxide. Diary
outcome measures included asthma-free days, average
rescue use/day, and average morning and evening FEV1 and
PEF. Safety was assessed at each visit by a standard ques-
tion about new medical problems, by oropharyngeal
examination, and by a standard question about voice
problems.Statistical methods
The sample size calculation was based on a previous down-
titration study25 assuming a mean daily FP dose of 500 mg on
FP and 375 mg on SFC, with 80% power using Wilcoxon rank
sum test (assuming P (X < Y) Z 0.278, corresponding to
a difference in log mean dose of 0.125, with SD 0.15). The
sample size of 27 per group was increased by 25% for
dropouts, giving a total sample size of 70. To show a clini-
cally important difference in AQLQ (0.5 units on a scale of
0e4), a sample size of 28 in each arm would be required for
80% power and significance 0.05.26 Analysis was by inten-
tion to treat. ANCOVA was used to test for differences in
mean FP dose between SFC and FP alone, adjusting for age,
gender, length of previous SFC use, site, baseline clinic
FEV1 and number of days in the study. ANCOVA was also
used to test for treatment differences in average rescue
use per day, average morning and evening PEF and FEV1.
Mixed model linear regression was used to test for treat-
ment differences at Visit 9 in clinic FEV1 and FVC, PD20,
ACQ, AQLQ and TAS. Optimal asthma control was analysed
using logistic regression, asthma-free days were analysed
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Figure 1 CONSORT diagram showing flow of participants through the study.
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sion, exacerbation rate was analysed using a Poisson
regression model, and minimum effective FP dose was
analysed using ordinal logistic regression.
A multivariate approach was used to assess the inde-
pendent effects of the biomarkers (PD20 methacholine,
FeNO, sputum eosinophils, sputum neutrophils, blood
eosinophils, number of IgE particles from nasal samplers) on
mean daily FP dose after adjustment for each other. The
covariates of treatment group, number of days on treat-
ment, and duration of SFC treatment prior to enrolment
were included in all regression analyses.Table 1 Demographic and baseline characteristics at study ent
Age, years
Sex, female (%)
Courses of oral or systemic steroids in last year
Never smoked/Former smoker, n
Smoking history, pack years
FEV1 L
FEV1 % predicted
FVC L
FVC % predicted
Asthma Control Questionnaire
Total Asthma Score
Baseline diary measures
Mean morning FEV1 % predicted
Mean morning PEF % predicted
Mean rescue use, occasions/day
% Asthma-free days
Mean and standard deviation unless otherwise indicated.Results
Eighty-two subjects were randomized from 3 sites; 41
received SFC and 41 received FP (Fig. 1). Table 1 shows
baseline and demographic characteristics. Prior to entry,
72% subjects were using SFC 50/500 mg bd by Diskus and 28%
were using SFC 25/250 mg 2  bd by pMDI, with no differ-
ence between randomization groups. At enrolment, most
participants had well-controlled asthma, with mild airway
obstruction, symptoms on only about 1/3 of days, and mean
ACQ values below 1.0.27 Disease activity, assessed prior to
dose reduction, was also well-controlled in most subjectsry.
SFC (n Z 41) FP (n Z 41)
45.0 (15.33) 49.1 (17.07)
21 (51%) 24 (58%)
1.6 (2.4) 1.5 (2.1)
27/14 26/15
4.5 (3.7) 3.0 (3.1)
2.86 (0.88) 2.58 (0.89)
86.31 (21.43) 83.27 (21.26)
3.88 (1.04) 3.59 (0.97)
99.53 (23.14) 97.66 (20.53)
0.93 (0.66) 0.87 (0.65)
4.54 (1.99) 4.63 (2.17)
77.1 (18.4) 78.1 (19.2)
90.0 (21.9) 90.1 (27.2)
0.68 (1.02) 0.52 (0.96)
62.6 (38.8) 68.0 (37.2)
Table 2 Participants’ baseline characteristics on randomized treatment, before commencement of ICS dose reduction.
SFC (n Z 40) FP (n Z 39)
Mean rescue use, occasions/day 0.82 (1.36) 0.86 (1.09)
Clinic FEV1 % predicted 84.6 (21.7) 82.0 (20.7)
Asthma Control Questionnaire 0.89 (0.66) 1.00 (0.71)
Total Asthma Score 4.58 (2.31) 4.92 (2.29)
PD20 FEV1 mmol methacholine, geometric mean (SD) 12.9 (2.8) (n Z 35) 12.2 (3.0) (n Z 34)
Mean morning PEF, L/min 435 (99) 395 (120)
Mean evening PEF, L/min 437 (98) 396 (120)
FeNO ppb, median (range) 7.05 (1.4e21.8) (n Z 28) 7.9 (0.1e36.4) (n Z 29)
Blood eosinophils 109/L 0.27 (0.13) (n Z 37) 0.33 (0.41) (n Z 38)
Sputum eosinophils %; geometric mean (SD) 0.9 (2.9) (n Z 22) 0.9 (1.9) (n Z 26)
Nasal samplers
Dermatophagoides pteronyssinus 1, pg 1978 (3817) 1689 (2844)
IgE, number of particles 30 (21) 44 (40)
Above data were from Visit 3, 4 weeks after randomization to SFC or FP, or, for diary variables, the 2 weeks before Visit 3.
Mean (standard deviation) unless otherwise indicated. Total Asthma Score (range 0e12, higher numbers Z worse asthma control).
PD20FEV1 e provocative dose of methacholine causing a 20% fall in FEV1; PEF e peak expiratory flow; FeNO e fractional concentration of
exhaled nitric oxide.
1114 H.K. Reddel et al.(Table 2); only 15% participants had airway hyper-
responsiveness (AHR, PD20 < 3.2 mmol), 25% had elevated
FeNO (>13.2ppb), and 24% had increased sputum eosino-
phils (>1.01%28). At Visit 1, 34 subjects (42%) reported voice
problems in the previous 8 weeks, and 3 subjects (4%) had
clinical evidence of oropharyngeal candidiasis.Table 3 Primary and secondary outcome measures.
SFC (n Z 41)
Treatment phase (weeks 1e52)
Mean daily FP dose,a mg 721
Minimum effective FP dose, mg 534
Morning PEF, L/min 426
Evening PEF, L/min 429
Morning FEV1, L 2.44
Evening FEV1, L 2.42
Rescue use, occasions/day 0.67
Asthma-free days, median % 71.4%
PD20 FEV1 methacholine, mmol, geometric mean 11.8
Moderate exacerbations (treated with double
study med), annualized rate
2.06
Severe exacerbations (treated with OCS),
annualized rate
0.20
Final visit (week 52) SFC (n Z 33)
Clinic FEV1, L 2.66
Clinic FVC, L 3.74
ACQ 1.11
AQLQ 1.35
Total Asthma Score 4.55
Sputum eosinophils, % 0.97 (n Z 16)
Blood eosinophils 10^9/L 0.32 (n Z 30)
Exhaled nitric oxide, ppb 9.82 (n Z 25)
a Primary outcome measure. FP e fluticasone propionate. SFC e
methacholine causing a 20% fall in FEV1. ACQ e Asthma Control
Questionnaire.Sixty subjects (73%) completed all nine study visits (SFC
80%, FP 66%, p Z 0.13; Fig. 1). Median adherence with
twice daily electronic diary and spirometric monitoring was
87%. There were 132 dose reduction attempts in 82
patients. Although the primary outcome (mean daily FP
dose) was lower with SFC than FP (721 mg vs 816 mg), theFP (n Z 41) Adjusted mean difference SFC-FP, (95% CI)
816 44.1 (133.9, 45.6), p Z 0.33
724 Odds ratio 3.37 (1.33, 8.16), p Z 0.005
398 28.3 (18.2, 38.5), p < 0.001
397 31.5 (21.4, 41.6), p < 0.001
2.36 0.07 (0.01, 0.16), p Z 0.09
2.34 0.08 (0.00, 0.17), p Z 0.049
0.53 0.12 (0.43, 0.18); p Z 0.4
54.8% 9.64 (3.27, 27.11); p Z 0.1
12.2 0.90 (0.60, 1.35), p Z 0.6
3.71 Rate ratio 0.55 (0.42, 0.74), p < 0.001
0.31 Rate ratio 0.66 (0.29, 1.52), p Z 0.3
FP (n Z 27)
2.68 0.025 (0.08, 0.13), p Z 0.6
3.76 0.01 (0.16, 0.13), p Z 0.9
1.20 0.17 (0.44, 0.11), p Z 0.2
1.55 0.24 (0.7, 0.2), p Z 0.3
4.85 0.52 (1.5, 0.5), p Z 0.3
0.91 (n Z 14) N/A
0.30 (n Z 27) N/A
9.46 (n Z 22) N/A
salmeterol fluticasone combination. PD20 e provocative dose of
Questionnaire. AQLQ e Marks Asthma-related Quality of Life
Minimum effective dose of FP ( g)
Salmeterol/fluticasone
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Figure 2 Distribution of minimum effective dose of flutica-
sone propionate after dose-titration with salmeterol/flutica-
sone or fluticasone propionate. The minimum effective dose
was the lowest dose at which asthma remained stable and the
participant did not experience an exacerbation. Average of
minimum effective dose was 534 mg for SFC, and 724 mg for FP
(p Z 0.005). SFC Z salmeterol/fluticasone; FP Z fluticasone
propionate.
Down-titration from high dose combination therapy in asthma 1115difference was not significant (pZ 0.3, Table 3). Secondary
outcomes are also shown in Table 3 and Fig. 3. Minimum
effective FP dose was significantly lower with SFC (mean
534 mg vs 724 mg, p Z 0.005). A dose reduction of 50% or
more was achieved by 66% SFC and 46% FP subjects, and
a reduction of 80% or more by 41% and 15% subjects
respectively (Fig. 2). Moderate exacerbations treated with
doubled study medication were less frequent with SFC than
FP (adjusted annualized mean rate 2.06 vs 3.71, p < 0.001).
A post-hoc analysis showed that there was no significant
difference between SFC and FP in exacerbations treated
with oral corticosteroids (adjusted rate ratio 0.66, 95% CI
0.29, 1.52, p Z 0.3).
During randomized treatment, morning and evening
diary card PEF and evening FEV1 were significantly higher
with SFC than FP (p < 0.001 for each), but there were no
significant differences between SFC and FP in rescue b2-
agonist use (p Z 0.4), asthma-free days (median 71% vs
55%, p Z 0.14) or PD20FEV1 (p Z 0.6). At the end of down-
titration (Visit 9), there were no significant differences
between treatment groups in clinic FEV1 (pZ 0.6) or clinic
FVC, nor in ACQ (mean difference 0.17 units, p Z 0.2),
AQLQ (mean difference 0.24 units, p Z 0.3), or Total
Asthma Score (mean difference 0.5, p Z 0.3). No signif-
icant difference was seen in the proportion of subjects
classified as having optimal asthma control by the
composite measure of TAS, airway responsiveness and
exacerbations (12/39 vs 7/27, pZ 0.4). There were also no
significant differences in FeNO, and no trend to increasing
values. Sputum eosinophils remained suppressed (median
0.0% and 0.13% for SFC and FP respectively). There were no
significant differences in allergen exposure between
groups, and no significant changes during the study.
In multivariate analysis, baseline PD20 methacholine
was inversely associated with mean daily FP dose after
adjusting for baseline FeNO, blood eosinophils, treatmentgroup, days on treatment, and duration of prior Seretide
use (n Z 54, p Z 0.03, Table 4). When sputum eosinophils
were included, the coefficient remained the same but the
relationship became non-significant; however, only 24
participants had all biomarkers measured at baseline.
For individual dose reduction steps, univariate analysis
demonstrated a negative correlation between pre-reduc-
tion blood eosinophil level and the likelihood of dose
reduction failure (pZ 0.045), but sputum eosinophils were
not predictive of dose reduction failure.
Adverse events
Over 13 months, 94% subjects reported non-serious
adverse event(s), the most common being nasophar-
yngitis, reported by 22 SFC subjects (54%) and 21 FP
subjects (51%). Two serious adverse events were reported
with SFC (gallstones, severe respiratory tract infection)
and three with FP (bleeding haemorrhoids, oesophageal
narrowing, and a cerebral arterio-venous malformation,
thought to have been congenital). None of the serious
adverse events was considered to be related to study
medication. Clinical evidence of oral candidiasis was
recorded for 8 subjects (20%) receiving SFC and 5 (12%)
receiving FP. In response to the voice question, three-
quarters of subjects (SFC 31 [76%]; FP 32 [78%]) reported
voice problems at one or more visits. Post hoc analysis
showed that subjects reporting dysphonia at their final
visit had a higher minimum effective dose (mean 840 vs
600 mg, p Z 0.05).
Discussion
This study was designed to evaluate whether, in patients
already stabilized on high dose ICS/LABA, greater down-
titration could be achieved with ICS/LABA than with ICS
alone while maintaining good asthma control, and to
investigate factors predicting success or failure of dose
reduction. Although the primary outcome measure, mean
daily ICS dose, was lower with SFC compared to FP, the
difference was not statistically significant. However, the
minimum effective dose, defined as the lowest ICS dose at
which a subject remained clinically stable, was signifi-
cantly lower with SFC, with 41% of participants achieving
80% or greater reduction in their ICS dose compared with
15% randomized to FP. Gradual dose reduction was ach-
ieved in the study population without significant loss of
clinical asthma control or evidence of increased disease
activity.
This study was planned in the context of studies about
high dose ICS and ICS/LABA,25,29 and widespread commu-
nity prescribing of high dose ICS/LABA.30 Although asthma
guidelines have always advocated down-titration of treat-
ment once asthma is well-controlled,31,32 there is little
evidence for how this should be done, and once patients
are prescribed high intensity medications for asthma,
clinicians appear to be reluctant to reduce treatment. For
example, when presented with a case vignette of a young
woman with no co-morbidities, who had wheezed only once
in the past 2 weeks, had FEV1 90% predicted with no
unscheduled visits for asthma in the previous 6 months, and
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Figure 3 Mean daily fluticasone dose and measures of asthma control during down-titration with salmeterol/fluticasone or
fluticasone propionate. Down-titration was gradual, aimed at maintaining good asthma control. a: mean daily fluticasone dose
(mcg/day), mean  SD; the adjusted mean difference between salmeterol/fluticasone and fluticasone was 44.1 mg (95% CI
133.9, 45.6, p Z 0.33); b: Asthma Control Questionnaire score, median  IQR; c: pre-bronchodilator FEV1, mean  SD. No
significant differences were seen between treatment groups for any of these outcomes.
Table 4 Baseline predictors of mean daily fluticasone dose from multivariate regression analysis.
Model Components Coefficient p value
Model 1 (n Z 54)
AHR (Log2PD20) 35.2 (67.6 to 2.8) 0.03
Blood Eosinophils (109/L) 105.3 (29.9 to 240.5) 0.12
eNO (ppb) 2.7 (9.7 to 4.2) 0.44
Model 2 (n Z 24)
AHR (Log2PD20) 35.8 (90.4 to 18.9) 0.18
Blood Eosinophils (109/L) 111.5 (32.0 to 255.0) 0.12
eNO (ppb) 4.6 (14.6 to 5.3) 0.34
Sputum Eosinophils (%) 22.9 (47.0 to 1.2) 0.06
AHR Z airway hyperresponsiveness, ppb Z parts per billion. Both models also adjusted for treatment group, days on treatment and
duration of Seretide prior to study.
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Down-titration from high dose combination therapy in asthma 1117who was treated with high dose ICS, LABA and leukotriene
modifier, only 29% of family physicians and 51% of pulmo-
nary specialists would step-down her treatment.33
Our study differed from previous down-titration studies
in two major respects. First, most participants had
already taken high dose ICS/LABA (2000 mg/day beclo-
methasone equivalent) for more than 6 months, and would
be likely to have already achieved maximal improvement
in asthma control.25 This was confirmed by baseline
characteristics of mild airway obstruction and low ACQ
(good clinical asthma control), and low levels of AHR,
FeNO and sputum eosinophils (well-controlled disease
activity). Second, ICS dose was gradually reduced over 12
months with a clinical strategy designed to maintain
asthma control rather than to reduce to the point of
exacerbation. Our previous down-titration study with ICS
alone25 used a similar algorithm but patients had only
taken high dose ICS for 8 weeks. To our knowledge, the
only previous study examining down-titration from high
long-term ICS doses is the study by Hawkins and
colleagues7; in this study, with baseline mean ICS dose of
1400 mg beclomethasone equivalent, the aim was to assess
whether ICS dose could be safely stepped down, and the
primary outcome measure was severe exacerbations
identified by use of oral corticosteroids. Each patient in
the step-down group could have their baseline ICS dose
halved if asthma was well-controlled, but LABA (taken by
34% participants) was not withdrawn; the comparison was
with no dose reduction.
In the present study, the failure to achieve statistical
significance in the primary outcome variable despite
a significant difference in minimum effective dose was
likely due to several factors. Mean daily dose for both
groups (SFC 721 mg/day, FP 816 mg/day) was substantially
higher than anticipated in the sample size calculation,
suggesting that the dose reduction schedule, although
safe, may have been too cautious. At these high dose
levels, a sample size of 110 in each group would have been
required for the difference to be significant. In the study by
Hawkins and colleagues,7 in which a significant difference
was found in mean daily ICS dose, no dose reduction was
permitted in the control arm, and the dose could not be
increased in the step-down arm if dose reduction was
unsuccessful or asthma was poorly-controlled. In the
present study, averaging of mean daily FP dose over the
whole 52-week treatment period, for 12 weeks of which
(23% of study duration) all subjects received FP 1000 mg/
day, would also reduce the potential for a significant
difference in mean daily dose to be achieved between
groups, although this may have been balanced by the
numerically higher rate of withdrawals in the FP arm. At
study end, asthma was still well-controlled in both groups,
so many subjects may still have been over-treated with ICS,
given the flat dose response for efficacy of FP over 500 mg/
day.34 In addition to implications for choice of primary
outcome, these factors also have implications for clinical
practice, namely, that delaying decisions about down-
titration for even a few months can have a long-lasting
impact on a patient’s cumulative drug exposure.
Nevertheless, some significant differences were
observed between SFC and FP which are consistent with the
known effects of LABA. Ambulatory lung function wassubstantially higher with SFC (mean differences in PEF
around 30L/min), indicating an ongoing bronchodilator
effect. Asthma exacerbations were also significantly lower
with SFC. A recent meta-analysis showed that ICS/LABA
leads to greater reduction in exacerbations than ICS alone
at similar doses, but not when the comparator is higher
dose ICS.35 In the present study, the rate of moderate
exacerbations was high for both groups, particularly given
the evidence of well-controlled asthma at entry. A low
proportion of exacerbations required oral corticosteroids
compared with other studies,36,37 and the rate was similar
to the year prior to enrolment. This suggests that our pre-
specified diary-based criteria for diagnosis of moderate
exacerbations were too sensitive and/or lacked specificity.
This in turn contributed to maintenance of higher than
anticipated ICS doses, via the dose-titration protocol. As
outlined in the recent ATS/ERS Task Force report on asthma
control and exacerbations, the development and validation
of objective criteria for prospectively identifying asthma
exacerbations in clinical trials remains a challenge.38
By contrast with meta-analyses comparing ICS/LABA
with same dose or higher dose ICS,35 other measures of
asthma control such as ACQ, asthma-free days and
asthma-related quality of life were not significantly
different between SFC and FP. This difference in findings
is likely due to ICS doses being high compared with in the
meta-analyses (mean daily dose of 400 mg/day CFC-
beclomethasone equivalent).35
The lack of difference in rescue b2-agonist use between
SFC and FP, despite a slight increase in the FP group after
randomization, was unexpected. A similar effect was noted
by Godard and colleagues.13 Given that ambulatory lung
function was substantially higher with ICS/LABA in both
studies, this suggests that factors other than airway
obstruction, such as tachyphylaxis or habitual use, may
have contributed to ongoing use of rescue b2-agonist. This
should be further investigated, since continuing use of
rescue b2-agonist may contribute to prescribing of higher
doses of ICS/LABA in the community.
Secondary objectives of the study were to demonstrate
whether the success or failure of ICS down-titration, as
indicated by mean daily ICS dose and level of asthma
control, was predicted by features of underlying disease
activity (AHR and/or airway inflammation). These analyses
were limited by incomplete data for induced sputum and
FeNO at some sites. For individual down-titration steps,
the only parameter which predicted outcome was blood
eosinophil count. In population studies, this simple
measure is an independent predictor of long-term
outcomes including mortality,39,40 and high baseline blood
eosinophil count predicts loss of clinical control during
rapid ICS down-titration.41 Unlike other investigators,6 we
did not find that sputum eosinophils predicted failure of
a subsequent dose-reduction step, but this may have been
due to the suppression of sputum eosinophilia at baseline
and the lack of dose response for inflammatory markers at
high doses. It may also have been due to the different
sputum processing methodology, in which samples were
frozen21 to allow analysis at a single site. This approach is
reproducible, and has only a minor effect on sputum
eosinophils.21,42 However there is loss of neutrophils,21,42
and unexpected cell loss cannot be excluded as a reason
1118 H.K. Reddel et al.for failing to find a predictive effect of sputum eosino-
phils. These factors may limit the applicability of the
freezing technique for future studies.
Previous studies indicate that AHR reflects an important
aspect of asthma control,38 and predicts exacerbations,43,44
loss of control with ICS reduction,6 and shorter time to exac-
erbation after ICSwithdrawal.45 In the present study, baseline
PD20 was the only significant predictor of mean daily ICS dose
during down-titration. Juniper and colleagues reported in
1981 that direct AHR was a significant predictor of the
minimum ICS dose required to control asthma symptoms.46
The rate of routinely-recorded adverse events was
consistent with other studies of high dose SFC and FP. A
high proportion of subjects in both groups reported voice
problems, consistent with the findings of Foster and
colleagues,47 but higher than in standard adverse event
records for studies with similar FP doses.29 While direct
questioning may increase the reporting of symptoms,
patients may fail to perceive voice changes as a “medical
problem”, so standard Adverse Event records may under-
estimate the true incidence of dysphonia.
The present study is the only study to date to examine
the impact of withdrawal of LABA from patients taking high
dose ICS/LABA, so it is highly relevant to the recent FDA
recommendation that LABA should be discontinued, if
possible, once asthma control is achieved.11 While our
study suggests that this can be achieved under careful
supervision utilizing an objective assessment process, the
challenges for primary care in achieving this safely outside
a closely monitored setting are complex. This study
suggests that ICS/LABA maintains better lung function and
lower exacerbation rates during supervised down-titration,
and that the minimum effective dose of ICS is higher if LABA
is not used, potentially increasing the risk of ICS-related
side-effects. Given the FDA ruling, more studies prospec-
tively testing down-titration schedules are needed to indi-
cate the rate at which the minimum effective dose can be
achieved and whether it remains the case that more
patients are likely to sustain good control on combination
ICS/LABA therapy than ICS alone.
Conclusions
In conclusion, this study showed that patients with well
controlled asthma taking high dose ICS/LABA can safely
undertake a substantial reduction in ICS dose, to lower
levels than can be achieved with ICS alone, without loss of
clinical asthma control or evidence of increasing disease
activity. The lack of difference in average daily ICS dose in
this study highlights the importance of promptly estab-
lishing the minimum effective dose for each patient. Use
of biomarkers such as blood eosinophils and AHR which
predict dose reduction outcomes provides the opportunity
to tailor treatment to the needs of individual patients.
The finding of similar usage of rescue b2-agonist in
patients receiving SFC and FP alone indicates the need for
monitoring indicators of both bronchodilatation and
bronchoprotection in patients receiving LABA therapy.
Further studies can now be undertaken in patients on
high-dose ICS/LABA, using a less cautious down-titration
schedule, to facilitate minimization of ICS doses in clinical
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